Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.51 |
| ▸ | RAB9A | P51151 | 5/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | FAAH | O00519 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL494360 | 0.89 | TSHR (0.53) | NPC1RAB9ASMN1; SMN2TP53TSHR | |
| SCHEMBL493598 | 0.81 | NPC1 (0.58) | NPC1RAB9ASMN1; SMN2TP53TSHR | |
| SCHEMBL493923 | 0.80 | KMT2A (0.65) | MAPTKMT2A | |
| SCHEMBL493476 | 0.76 | FABP4 (0.48) | NPC1RAB9ASMN1; SMN2TSHRMAPT | |
| SCHEMBL493611 | 0.76 | SMYD3 (0.43) | NPC1RAB9ASMN1; SMN2TP53TSHR | |
| SCHEMBL494598 | 0.74 | LMNA (0.44) | NPC1RAB9ASMN1; SMN2TSHRLMNA | |
| SCHEMBL493217 | 0.70 | GCGR (0.49) | — | |
| SCHEMBL493896 | 0.70 | FAAH (0.56) | NPC1RAB9ASMN1; SMN2TP53TSHR | |
| SCHEMBL493260 | 0.70 | SMN1; SMN2 (0.75) | NPC1RAB9ASMN1; SMN2TP53LMNA | |
| SCHEMBL15436312 | 0.69 | NPC1 (0.82) | NPC1RAB9ASMN1; SMN2TP53TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8106055-B2 | Substituted amide compounds | GRUENENTHAL GMBH (DE) | 2012-01-31 | — | — | US | disclosed |
| US-20080306084-A1 | Substituted Amide Compounds | GRUENENTHAL GMBH (DE) | 2008-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306084-A1 | Substituted Amide Compounds | OPRK1, NAA50, ACMSD | NPC1 519/4885RAB9A 2004/4885SMN1; SMN2 1729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.